Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11417
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrossmann, Mathisen
dc.contributor.authorZajac, Jeffrey Den
dc.date.accessioned2015-05-16T01:01:20Z-
dc.date.available2015-05-16T01:01:20Z-
dc.date.issued2012-01-09en
dc.identifier.citationAsian Journal of Andrology 2012; 14(2): 187-92en
dc.identifier.govdoc22231300en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11417en
dc.description.abstractAndrogen deprivation therapy (ADT) has been associated with a plethora of adverse effects, consistent with the androgen dependency of multiple reproductive and somatic tissues. One such tissue is the hemopoietic system, and one of the most predictable consequences of ADT is the development of anemia. Although anemia caused by ADT is rarely severe, ADT is often given to frail, elderly men with increased susceptibility to anemia due to multiple other causes. ADT-associated anemia may contribute to fatigue and reduced quality of life (QoL) in such men, although this requires further study. While anemia is an independent risk factor of mortality in men with prostate cancer, it is not known whether treatment of ADT-associated anemia alters clinically important outcomes, or whether treatment affects mortality. Awareness of the phenomenon of ADT-induced anemia should avoid unnecessary work-up in mild cases of normocytic normochromic anemia. However, assessment and treatment of more severe anemia may be required. This should be determined on an individual basis. In contrast to the well-described actions of ADT on erythropoiesis, its effect on other hemopoietic lineages has been less well elucidated. While preclinical studies have found roles for androgens in maturation and differentiated function of neutrophils, lymphocytes and platelets, the implications of these findings for men with prostate cancer receiving ADT require further studies.en
dc.language.isoenen
dc.subject.otherAndrogen Antagonists.adverse effects.pharmacology.therapeutic useen
dc.subject.otherAnemia.chemically induced.epidemiologyen
dc.subject.otherErythropoiesis.drug effectsen
dc.subject.otherHematopoiesis.drug effectsen
dc.subject.otherHumansen
dc.subject.otherIncidenceen
dc.subject.otherMaleen
dc.subject.otherProstatic Neoplasms.drug therapyen
dc.titleHematological changes during androgen deprivation therapy.en
dc.typeJournal Articleen
dc.identifier.journaltitleAsian journal of andrologyen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Northern Health, University of Melbourne, Victoria, Australiaen
dc.identifier.doi10.1038/aja.2011.102en
dc.description.pages187-92en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/22231300en
dc.identifier.orcid0000-0001-8261-3457-
dc.type.austinJournal Articleen
local.name.researcherGrossmann, Mathis
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

44
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.